SCHEMBL4679895

SCHEMBL4679895

NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)[CH]CCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 1/20 0.48
ERAP2 Q6P179 2/20 0.43
ERAP1 Q9NZ08 2/20 0.43
IL1RN P18510 1/20 0.43
PSMB8 P28062 1/20 0.43
PSMB5 P28074 1/20 0.43
CTSL P07711 1/20 0.42
HPGDS O60760 4/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
PPARG P37231 1/20 0.42
PARP1 P09874 1/20 0.42
PARP3 Q9Y6F1 1/20 0.42
CAPN1 P07384 1/20 0.42
CTSB P07858 1/20 0.42
LNPEP Q9UIQ6 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
MMP2 P08253 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679200 0.83 FCER2 (0.56) CTSLPARP1PARP3CAPN1CTSB
SCHEMBL4677385 0.81 FCER2 (0.45) CTSLHPGDSPARP1PARP3CAPN1
SCHEMBL4679398 0.78 GPR52 (0.47) ERAP2ERAP1GAACAPN1LNPEP
SCHEMBL4682047 0.77 HPGDS (0.53) HPGDSPPARGCAPN1CTSBMMP1
SCHEMBL18262574 0.77 CA2 (0.49) PSMB8PSMB5HPGDSPPARGADAMTS5
SCHEMBL18262572 0.77 CA2 (0.49) PSMB8PSMB5HPGDSPPARGADAMTS5
SCHEMBL27695921 0.77 HPGDS (0.65) CTSLHPGDSGAA
SCHEMBL11574131 0.76 PSMB8 (0.51) PSMB8PSMB5HPGDSADAMTS5MMP2
SCHEMBL4679436 0.76 F10 (0.51) CTSLPARP1PARP3CAPN1CTSB
SCHEMBL4683269 0.76 ECE1 (0.56) ERAP2ERAP1IL1RNHPGDSLNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP claimed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US claimed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP claimed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO claimed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155803-A1 Protease inhibitors DPP7, DPP9, DPP3 NOS2 1862/4885ERAP2 360/4885ERAP1 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.